Citation Information :
Balakrishnan D, Garg R. Emerging Trends in Treatment of Hot Flashes at Menopause: A Review. J South Asian Feder Obs Gynae 2024; 16 (5):595-601.
Hot flashes represent a prevalent symptom prompting menopausal women to seek assistance. The utilization of treatment among these women is notably low, particularly in countries such as India, where women may display hesitancy toward regular follow-up. Hormone replacement therapy (HRT) has been identified as the standard treatment for addressing hot flashes in menopausal women. Notably, several guidelines have advocated for the safe use of HRT in healthy women under the age of 60 who have entered menopause within the past decade. It is recommended that women with comorbidities undergo assessment and receive personalized treatment plans. Non-hormonal treatments and complementary therapies should be considered for women unable to undergo HRT. Additionally, emerging pharmaceuticals may serve as viable substitutes for traditional HRT. This review provides insight into both current and forthcoming treatments for hot flashes.
Duralde ER, Sobel TH, Manson JE. Management of perimenopausal and menopausal symptoms. BMJ 2023;382:e072612. DOI: 10.1136/bmj-2022-072612.
United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2024: Summary of Results 2024; UN DESA/POP/2024. Available from: http://population.un.org/wpp/Publications/Files/WPP2024_Key-Messages.pdf.
Ambikairajah A, Walsh E, Cherbuin N. A review of menopause nomenclature. Reprod Health 2022;14(1):1–15. DOI: 10.1186/s12978022-01336-7.
Kundu S, Acharya SS. Exploring the triggers of premature and early menopause in India: A comprehensive analysis based on National Family Health Survey, 2019–2021. Sci Rep 2024;14(1):1–15. DOI: 10.1038/s41598-024-53536-9.
Evans KL, Millsteed J, Richmond JE, et al. Working sandwich generation women utilize strategies within and between roles to achieve role balance. PLoS One 2016 Jun 15;11(6):e0157469. DOI: 10.1371/journal.pone.0157469.
Lee SR, Cho MK, Cho YJ, et al. The 2020 menopausal hormone therapy guidelines. J Menopausal Med 2020;26(2):69–98. DOI: 10.6118/jmm.20000.
Delamater L, Santoro N. Management of the perimenopause. Clin Obstet Gynecol 2018;61(3):419–432. DOI: 10.1097/GRF.0000000000000389.
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175(4):531–539. DOI: 10.1001/jamainternmed.2014. 8063.
Harlow SD, Burnett-Bowie SM, Greendale GA, et al. Disparities in reproductive aging and midlife health between black and white women: The study of women's health across the nation (SWAN). Womens Midlife Health 2022;8(1):3. DOI: 10.1186/s40695-022-00073-y.
Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping oestrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010;17(5):946–954. DOI: 10.1097/gme.0b013e3181d76953.
Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control: A link to cardiovascular risk? Menopause 2010;17(3):456–461. DOI: 10.1097/gme.0b013e3181c7dea7.
Kligman L, Younus J. Management of hot flashes in women with breast cancer. Curr Oncol 2010;17(1):81–86. DOI: 10.3747/co.v17i1.473.
Richard W, Walker LM, Robinson JW Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved Ones. 2023. DOI: 10.1891/9780826184030.
Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: A review of pathophysiology and treatment modalities. Oncologist 2011;16(11):1658–1664. DOI: 10.1634/theoncologist.2011-0174.
Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34(3):211–127. DOI: 10.1016/j.yfrne.2013.07.003.
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study. Lancet 2023;401(10382):1091–1102. DOI: 10.1016/S0140-6736(23)00085-5.
Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: Scientific review. JAMA 2004;291(13):1610–1620. DOI: 10.1001/jama.291.13.1610.
Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028.
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100(11):3975–4011. DOI: 10.1210/jc.2015-2236.
Cobin RH, Goodman NF, AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause–2017 update. Endocr Prac 2017;23(7):869–881. DOI: 10.4158/EP171828.PS.
Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2020;26(4):181–209. DOI: 10.1177/2053369120957514.
Schnatz, Peter F. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause (New York, NY) 24.7 (2017): 728.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394(10204):1159–1168. DOI: 10.1016/S0140-6736(19)31709-X.
Chlebowski RT, Anderson GL, Aragaki AK. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA 2020;324(4):369–380. DOI: 10.1001/jama.2020.9482.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103–111. DOI: 10.1007/s10549-007-9523-x.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the Q Research and CPRD databases. BMJ 2020;371:m3873. DOI: 10.1136/bmj.m3873.
Silva FR, Grande AJ, Lacerda Macedo AC, et al. Meta-analysis of breast cancer risk in levonorgestrel-releasing intrauterine system users. Clin Breast Cancer 2021;21(6):497–508. DOI: 10.1016/j.clbc.2021.03.013.
Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2020;99(8):970–982. DOI: 10.1111/aogs.13817.
Liotta M, Escobar PF. Hormone replacement after breast cancer: Is it safe? Clin Obstet Gynecol 2011;54(1):173–179. DOI: 10.1097/GRF.0b013e3182083cbb.
Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;2015(3):CD002229. DOI: 10.1002/14651858.CD002229.pub4.
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007;115(7):840–845. DOI: 10.1161/CIRCULATIONAHA.106.642280.
Hirsch H, Manson JE. Menopausal symptom management in women with cardiovascular disease or vascular risk factors. Maturitas 2022;161:1–6. DOI: 10.1016/j.maturitas.2022.01.016. Epub: 29 Jan 2022.
Prior JC. Progesterone for treatment of symptomatic menopausal women. Climacteric 2018;21(4):358–365. DOI: 10.1080/13697137.2018.1472567.
Prior JC, Cameron A, Fung M, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. Sci Rep 2023;13(1):9082. DOI: 10.1038/s41598-023-35826-w. Erratum in: Sci Rep 2024 Jul 27;14(1):17229.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321–333. DOI: 10.1001/jama.288.3.321.
Anagnostis P, Lambrinoudaki I, Stevenson JC, et al. Menopause-associated risk of cardiovascular disease. Endocr Connect 2022;11(4): e210537. DOI: 10.1530/EC-21-0537.
Kaemmle LM, Stadler A, Janka H, et al. The impact of micronized progesterone on cardiovascular events–a systematic review. Climacteric 2022;25(4):327–336. DOI: 10.1080/13697137.2021.2022644.
Tremollieres F, Brincat M, Erel CT, et al. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas 2011;69(2):195–198. DOI: 10.1016/j.maturitas.2011. 03.011.
Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): A review. Menopause 2018;25(9):1033–1045. DOI: 10.1097/GME.0000000000001095.
The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel: Faubion SS, Crandall CJ, Davis L, et al. The 2022 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028.
Pickar JH, Yeh IT, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92(3):1018–1024. DOI: 10.1016/j.fertnstert.2009.05.094.
Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: A randomized controlled trial. Obstet Gynecol 2013;121(5):959–968. DOI: 10.1097/AOG.0b013e31828c5974.
Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: A randomized trial. J Clin Endocrinol Metab 2014;99(2):E189–E198. DOI: 10.1210/jc.2013-1707.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24(7):728–753. DOI: 10.1097/GME.0000000000000921.
Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50(3):222–230. DOI: 10.1016/j.maturitas.2004.06.001.
Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359(7):697–708. DOI: 10.1056/NEJMoa0800743.
Lumsden MA, Davies M, Sarri G. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline. JAMA Intern Med 2016;176(8):1205–1206. DOI:10.1001/jamainternmed.2016.2761.
Khan SJ, Kapoor E, Faubion SS, et al. Vasomotor symptoms during menopause: A practical guide on current treatments and future perspectives. Int J Womens Health 2023;15:273–287. DOI: 10.2147/IJWH.S365808.
Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: Prevalence and quality of life burden. Menopause. 2021;28(8):875–882. DOI: 10.1097/GME.0000000000001793.
Lee MS, Kim JI, Ha JY, et al. Yoga for menopausal symptoms: A systematic review. Menopause 2009;16(3):602–608. DOI: 10.1097/gme.0b013e31818ffe39.
Lindh-Astrand L, Nedstrand E, Wyon Y, et al. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004;48(2):97–105. DOI: 10.1016/S0378-5122(03)00187-7.
Tremblay A, Sheeran L, Aranda SK. Psychoeducational interventions to alleviate hot flashes: A systematic review. Menopause 2008;15(1):193–202. DOI: 10.1097/gme.0b013e31805c08dc.
North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause 2004;11(1):11–33. DOI: 10.1097/01.GME.0000108177.85442.71.
Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: A 20-year experience. Menopause 2008;15(4 Pt 1):655–660. DOI: 10.1097/gme.0b013e3181679150.
Piraccini E, Munakomi S, Chang KV. Stellate Ganglion Blocks. [Updated 2023 Aug 13]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2024.
Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: A systematic review. Menopause 2009;16(5):1065–1073. DOI: 10.1097/gme.0b013e3181a48abd.
Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: Results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30(33):4124–4133. DOI: 10.1200/JCO.2012.41.8525.
Elkins GR, Fisher WI, Johnson AK, et al. Clinical hypnosis in the treatment of postmenopausal hot flashes: A randomized controlled trial. Menopause 2013;20(3):291–298. DOI 10.1097/gme.0b013e31826ce3ed.
Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): Part 1. Vasomotor symptoms and overall safety. Menopause 2020;27(8):848–857. DOI: 10.1097/GME.0000000000001561.
Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: Results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause 2020;27(12):1350–1356. DOI: 10.1097/GME.0000000000001621.
Simon J, Anderson RA, Ballantyne E, et al. OR11-03 NT-814, a non-hormonal dual neurokinin 1,3 receptor antagonist markedly improves vasomotor symptoms in post-menopausal women; results of a randomised, double-blind, placebo-controlled, dose-finding study (SWITCH-1). J Endocr Soc 2020;4(Supplement_1):OR11-03. DOI: 10.1210/jendso/bvaa046.2071.
Trower M, Anderson RA, Ballantyne E, et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: A placebo-controlled, randomized trial. Menopause 2020;27(5):498–505. DOI: 10.1097/GME.0000000000001500.